Literature DB >> 8392628

Conserved residues Pro-109 and Asp-116 are required for interaction of the human immunodeficiency virus type 1 integrase protein with its viral DNA substrate.

M Drelich1, M Haenggi, J Mous.   

Abstract

The human immunodeficiency virus type 1 integrase protein can be specifically cross-linked to viral long terminal repeat substrate oligonucleotides in vitro by using UV light. Site-directed mutagenesis and deletion analyses were used to define the domains involved in the interaction of integrase with the viral DNA substrate. Our results showed that mutation of conserved residues Pro-109 and Asp-116, which are found to be critical for the endonuclease and integration activities of IN protein, abolished the ability of the protein to cross-link to its DNA substrate. Furthermore, deletion analysis experiments showed that removal of 39 amino acids from the amino terminus and deletion of 15 amino acids from the carboxyl terminus abolished DNA cross-linking.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8392628      PMCID: PMC237894     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  17 in total

1.  Identification of conserved amino acid residues critical for human immunodeficiency virus type 1 integrase function in vitro.

Authors:  A Engelman; R Craigie
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

2.  Analysis of mutations in the integration function of Moloney murine leukemia virus: effects on DNA binding and cutting.

Authors:  M J Roth; P Schwartzberg; N Tanese; S P Goff
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

3.  Retroviral integrase domains: DNA binding and the recognition of LTR sequences.

Authors:  E Khan; J P Mack; R A Katz; J Kulkosky; A M Skalka
Journal:  Nucleic Acids Res       Date:  1991-02-25       Impact factor: 16.971

4.  Human immunodeficiency virus integrase protein requires a subterminal position of its viral DNA recognition sequence for efficient cleavage.

Authors:  C Vink; D C van Gent; Y Elgersma; R H Plasterk
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

5.  Computer analysis of retroviral pol genes: assignment of enzymatic functions to specific sequences and homologies with nonviral enzymes.

Authors:  M S Johnson; M A McClure; D F Feng; J Gray; R F Doolittle
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

6.  The avian retroviral IN protein is both necessary and sufficient for integrative recombination in vitro.

Authors:  R A Katz; G Merkel; J Kulkosky; J Leis; A M Skalka
Journal:  Cell       Date:  1990-10-05       Impact factor: 41.582

7.  Human immunodeficiency virus integration protein expressed in Escherichia coli possesses selective DNA cleaving activity.

Authors:  P A Sherman; J A Fyfe
Journal:  Proc Natl Acad Sci U S A       Date:  1990-07       Impact factor: 11.205

8.  The avian retroviral integration protein cleaves the terminal sequences of linear viral DNA at the in vivo sites of integration.

Authors:  M Katzman; R A Katz; A M Skalka; J Leis
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

9.  Activities of human immunodeficiency virus (HIV) integration protein in vitro: specific cleavage and integration of HIV DNA.

Authors:  F D Bushman; R Craigie
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

10.  DNA binding properties of the integrase proteins of human immunodeficiency viruses types 1 and 2.

Authors:  D C van Gent; Y Elgersma; M W Bolk; C Vink; R H Plasterk
Journal:  Nucleic Acids Res       Date:  1991-07-25       Impact factor: 16.971

View more
  14 in total

1.  Mutations in nonconserved domains of Ty3 integrase affect multiple stages of the Ty3 life cycle.

Authors:  M H Nymark-McMahon; S B Sandmeyer
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

2.  The role of manganese in promoting multimerization and assembly of human immunodeficiency virus type 1 integrase as a catalytically active complex on immobilized long terminal repeat substrates.

Authors:  A L Wolfe; P J Felock; J C Hastings; C U Blau; D J Hazuda
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

3.  Reversion of a human immunodeficiency virus type 1 integrase mutant at a second site restores enzyme function and virus infectivity.

Authors:  B Taddeo; F Carlini; P Verani; A Engelman
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

4.  Effects of mutations in residues near the active site of human immunodeficiency virus type 1 integrase on specific enzyme-substrate interactions.

Authors:  J L Gerton; S Ohgi; M Olsen; J DeRisi; P O Brown
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

5.  Mapping domains of retroviral integrase responsible for viral DNA specificity and target site selection by analysis of chimeras between human immunodeficiency virus type 1 and visna virus integrases.

Authors:  M Katzman; M Sudol
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

6.  Monoclonal antibodies against Rous sarcoma virus integrase protein exert differential effects on integrase function in vitro.

Authors:  B Müller; D Bizub-Bender; M D Andrake; K S Jones; A M Skalka
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

7.  The core and carboxyl-terminal domains of the integrase protein of human immunodeficiency virus type 1 each contribute to nonspecific DNA binding.

Authors:  A Engelman; A B Hickman; R Craigie
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

8.  Human immunodeficiency virus type 1 integrase: effect on viral replication of mutations at highly conserved residues.

Authors:  P M Cannon; W Wilson; E Byles; S M Kingsman; A J Kingsman
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

9.  In vitro activities of purified visna virus integrase.

Authors:  M Katzman; M Sudol
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

10.  Molecular and genetic determinants of rous sarcoma virus integrase for concerted DNA integration.

Authors:  Roger Chiu; Duane P Grandgenett
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.